Terms: = Colorectal cancer AND CIC, ENSG00000079432, 23152, Q96RK0, KIAA0306
51 results:
1. Clinicopathological factors predict residual lymph node metastasis in locally advanced rectal cancer with ypT0-2 after neoadjuvant chemoradiotherapy.
Cui Y; Song M; Tie J; Li S; Wang H; Zhang Y; Geng J; Liu Z; Teng H; Sui X; Zhu X; Cai Y; Li Y; Wang W
J Cancer Res Clin Oncol; 2024 Apr; 150(4):176. PubMed ID: 38575793
[TBL] [Abstract] [Full Text] [Related]
2. Development and validation of comprehensive nomograms from the SEER database for predicting early mortality in metastatic rectal cancer patients.
Li Y; Tao T; Liu Y
BMC Gastroenterol; 2024 Feb; 24(1):89. PubMed ID: 38408896
[TBL] [Abstract] [Full Text] [Related]
3. A CT-based radiomics nomogram for predicting histopathologic growth patterns of colorectal liver metastases.
Sun C; Liu X; Sun J; Dong L; Wei F; Bao C; Zhong J; Li Y
J Cancer Res Clin Oncol; 2023 Sep; 149(12):9543-9555. PubMed ID: 37221440
[TBL] [Abstract] [Full Text] [Related]
4. A novel prognostic model for patients with colon adenocarcinoma.
Yin C; Wang W; Cao W; Chen Y; Sun X; He K
Front Endocrinol (Lausanne); 2023; 14():1133554. PubMed ID: 36923226
[TBL] [Abstract] [Full Text] [Related]
5. Construction of a novel choline metabolism-related signature to predict prognosis, immune landscape, and chemotherapy response in colon adenocarcinoma.
Liu C; Liu D; Wang F; Liu Y; Xie J; Xie J; Xie Y
Front Immunol; 2022; 13():1038927. PubMed ID: 36451813
[TBL] [Abstract] [Full Text] [Related]
6. Sacrococcygeal teratoma: Long-term outcomes. A UK CCLG Surgeons Group Nationwide Study.
Braungart S; James EC; Powis M; Gabra H; ; Losty PD
Pediatr Blood Cancer; 2023 Jan; 70(1):e29994. PubMed ID: 36229941
[TBL] [Abstract] [Full Text] [Related]
7. Patterns of metastases progression- The linear parallel ratio.
Gofrit ON; Gofrit B; Roditi Y; Popovtzer A; Frank S; Sosna J; Goldberg SN
PLoS One; 2022; 17(9):e0274942. PubMed ID: 36129954
[TBL] [Abstract] [Full Text] [Related]
8. Single-cell landscape and clinical outcomes of infiltrating B cells in colorectal cancer.
Xia J; Xie Z; Niu G; Lu Z; Wang Z; Xing Y; Ren J; Hu Z; Hong R; Cao Z; Han S; Chu Y; Liu R; Ke C
Immunology; 2023 Jan; 168(1):135-151. PubMed ID: 36082430
[TBL] [Abstract] [Full Text] [Related]
9. SLC25A1 promotes tumor growth and survival by reprogramming energy metabolism in colorectal cancer.
Yang Y; He J; Zhang B; Zhang Z; Jia G; Liu S; Wu T; He X; Wang N
Cell Death Dis; 2021 Nov; 12(12):1108. PubMed ID: 34839347
[TBL] [Abstract] [Full Text] [Related]
10. TRAIL signaling promotes entosis in colorectal cancer.
Bozkurt E; Düssmann H; Salvucci M; Cavanagh BL; Van Schaeybroeck S; Longley DB; Martin SJ; Prehn JHM
J Cell Biol; 2021 Nov; 220(11):. PubMed ID: 34546352
[TBL] [Abstract] [Full Text] [Related]
11. FOLFOX Therapy Induces Feedback Upregulation of CD44v6 through YB-1 to Maintain Stemness in Colon Initiating Cells.
Ghatak S; Hascall VC; Markwald RR; Misra S
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33451103
[TBL] [Abstract] [Full Text] [Related]
12. Advances into Understanding the Vital Role of the Mitochondrial Citrate Carrier (cic) in Metabolic Diseases.
Peng R; Zhang M; Wang H; Lin J; Wang H; Wang F; Liu L; Zhao Q; Liu J
Pharmacol Res; 2020 Nov; 161():105132. PubMed ID: 32814170
[TBL] [Abstract] [Full Text] [Related]
13. Age, sex, and specific gene mutations affect the effects of immune checkpoint inhibitors in colorectal cancer.
Lin A; Zhang H; Hu X; Chen X; Wu G; Luo P; Zhang J
Pharmacol Res; 2020 Sep; 159():105028. PubMed ID: 32569820
[TBL] [Abstract] [Full Text] [Related]
14. A novel BMI-1 inhibitor QW24 for the treatment of stem-like colorectal cancer.
Wang J; Xing Y; Wang Y; He Y; Wang L; Peng S; Yang L; Xie J; Li X; Qiu W; Yi Z; Liu M
J Exp Clin Cancer Res; 2019 Oct; 38(1):422. PubMed ID: 31640758
[TBL] [Abstract] [Full Text] [Related]
15. Heterotypic cell-in-cell structures in colon cancer can be regulated by IL-6 and lead to tumor immune escape.
Wang S; Li L; Zhou Y; He Y; Wei Y; Tao A
Exp Cell Res; 2019 Sep; 382(1):111447. PubMed ID: 31150612
[TBL] [Abstract] [Full Text] [Related]
16. Exosomes, metastases, and the miracle of cancer stem cell markers.
Wang Z; Zöller M
Cancer Metastasis Rev; 2019 Jun; 38(1-2):259-295. PubMed ID: 31030373
[TBL] [Abstract] [Full Text] [Related]
17. Claudin7-dependent exosome-promoted reprogramming of nonmetastasizing tumor cells.
Kyuno D; Zhao K; Schnölzer M; Provaznik J; Hackert T; Zöller M
Int J Cancer; 2019 Oct; 145(8):2182-2200. PubMed ID: 30945750
[TBL] [Abstract] [Full Text] [Related]
18. A rapid in vitro methodology for simultaneous target discovery and antibody generation against functional cell subpopulations.
Nixon AML; Duque A; Yelle N; McLaughlin M; Davoudi S; Pedley NM; Haynes J; Brown KR; Pan J; Hart T; Gilbert PM; Singh SK; O'Brien CA; Sidhu SS; Moffat J
Sci Rep; 2019 Jan; 9(1):842. PubMed ID: 30696911
[TBL] [Abstract] [Full Text] [Related]
19. Poly(ADP-Ribose) Polymerase Inhibition Sensitizes colorectal cancer-Initiating Cells to Chemotherapy.
Jarrar A; Lotti F; DeVecchio J; Ferrandon S; Gantt G; Mace A; Karagkounis G; Orloff M; Venere M; Hitomi M; Lathia J; Rich JN; Kalady MF
Stem Cells; 2019 Jan; 37(1):42-53. PubMed ID: 30353615
[TBL] [Abstract] [Full Text] [Related]
20. Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets cancer-Initiating Cells in Preclinical Models of colorectal cancer.
Haynes J; McKee TD; Haller A; Wang Y; Leung C; Gendoo DMA; Lima-Fernandes E; Kreso A; Wolman R; Szentgyorgyi E; Vines DC; Haibe-Kains B; Wouters BG; Metser U; Jaffray DA; Smith M; O'Brien CA
Clin Cancer Res; 2018 May; 24(9):2116-2127. PubMed ID: 29476017
[No Abstract] [Full Text] [Related]
[Next]
